PharmAthene, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.pharmathene.com
Clinical Trials
5
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (100.0%)Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects
Phase 1
Completed
- Conditions
- Anthrax
- Interventions
- Biological: MDX1303Drug: Normal Saline for Injection
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- PharmAthene, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01265745
- Locations
- 🇺🇸
Quintiles Phase I Unit, Overland Park, Kansas, United States
Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use
Phase 1
Completed
- Conditions
- Allergic Reactions
- Interventions
- Drug: Valortim and Selected Components
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- PharmAthene, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01204866
- Locations
- 🇺🇸
Kansas City Allergy and Asthma, Overland Park, Kansas, United States
Ph1 Study of Valortim and Doxycycline in Humans
Phase 1
Terminated
- Conditions
- Anthrax
- Interventions
- Drug: Placebo Antibiotic and ValortimDrug: Placebo Antibiotic and Placebo Valortim
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- PharmAthene, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00964834
- Locations
- 🇺🇸
Quintiles Phase I Services, Overland Park, Kansas, United States
Ph1 Study of Valortim and Ciprofloxacin in Humans
Phase 1
Suspended
- Conditions
- Anthrax
- Interventions
- Other: Placebo Antibiotic and Placebo ValortimDrug: Placebo Antibiotic and Valortim
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- PharmAthene, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00964561
- Locations
- 🇺🇸
Quintiles Phase I Services, Overland Park, Kansas, United States
First Time in Human Study of Protexia
Phase 1
Completed
- Conditions
- Intervention for Nerve Agent Exposure
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- PharmAthene, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00744146
- Locations
- 🇺🇸
Quinitles Phase I Services, Overland Park, Kansas, United States
News
No news found